lifestyle.californiaconsumerbanking.com

Author: Arvinas Inc.

Arvinas and Pfizer Enter into a Transaction with Rigel Pharmaceuticals for the Exclusive Global Rights of VEPPANU (vepdegestrant)

May 12, 2026
Arvinas to Report First Quarter 2026 Financial Results on May 12, 2026

May 8, 2026
Arvinas Announces Positive Phase 1 Data for ARV-102 Showing Greater Than 50% LRRK2 Degradation in the CSF of Patients with Parkinson’s Disease Treated for 28 Days

May 2, 2026
Arvinas to Present Phase 1 Data for ARV-102, a PROTAC LRRK2 Degrader, in Oral Session at the 2026 International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders

May 1, 2026
Arvinas to Participate in Upcoming Investor Conferences

April 28, 2026
Arvinas to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026

March 10, 2026
Arvinas Announces Appointment of Randy Teel, Ph.D., as President, Chief Executive Officer, and Director

March 10, 2026